314 related articles for article (PubMed ID: 19906496)
1. Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases.
Jansen JF; Schöder H; Lee NY; Wang Y; Pfister DG; Fury MG; Stambuk HE; Humm JL; Koutcher JA; Shukla-Dave A
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1403-10. PubMed ID: 19906496
[TBL] [Abstract][Full Text] [Related]
2. Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET.
Jansen JF; Schöder H; Lee NY; Stambuk HE; Wang Y; Fury MG; Patel SG; Pfister DG; Shah JP; Koutcher JA; Shukla-Dave A
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):299-307. PubMed ID: 21236594
[TBL] [Abstract][Full Text] [Related]
3. Assessment of metastatic lymph nodes in head and neck squamous cell carcinomas using simultaneous
Chen J; Hagiwara M; Givi B; Schmidt B; Liu C; Chen Q; Logan J; Mikheev A; Rusinek H; Kim SG
Sci Rep; 2020 Nov; 10(1):20764. PubMed ID: 33247166
[TBL] [Abstract][Full Text] [Related]
4. Comparison of DCE-MRI kinetic parameters and FMISO-PET uptake parameters in head and neck cancer patients.
Simoncic U; Leibfarth S; Welz S; Schwenzer N; Schmidt H; Reischl G; Pfannenberg C; Fougère C; Nikolaou K; Zips D; Thorwarth D
Med Phys; 2017 Jun; 44(6):2358-2368. PubMed ID: 28317128
[TBL] [Abstract][Full Text] [Related]
5. 18F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1α expression in oral squamous cell carcinoma.
Sato J; Kitagawa Y; Yamazaki Y; Hata H; Okamoto S; Shiga T; Shindoh M; Kuge Y; Tamaki N
J Nucl Med; 2013 Jul; 54(7):1060-5. PubMed ID: 23699668
[TBL] [Abstract][Full Text] [Related]
6. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer.
Nehmeh SA; Lee NY; Schröder H; Squire O; Zanzonico PB; Erdi YE; Greco C; Mageras G; Pham HS; Larson SM; Ling CC; Humm JL
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):235-42. PubMed ID: 18086391
[TBL] [Abstract][Full Text] [Related]
7. Multiparametric Imaging of Tumor Hypoxia and Perfusion with
Grkovski M; Schöder H; Lee NY; Carlin SD; Beattie BJ; Riaz N; Leeman JE; O'Donoghue JA; Humm JL
J Nucl Med; 2017 Jul; 58(7):1072-1080. PubMed ID: 28183993
[TBL] [Abstract][Full Text] [Related]
8. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma.
Kikuchi M; Yamane T; Shinohara S; Fujiwara K; Hori SY; Tona Y; Yamazaki H; Naito Y; Senda M
Ann Nucl Med; 2011 Nov; 25(9):625-33. PubMed ID: 21720778
[TBL] [Abstract][Full Text] [Related]
9. The optimal
Gertsenshteyn I; Epel B; Ahluwalia A; Kim H; Fan X; Barth E; Zamora M; Markiewicz E; Tsai HM; Sundramoorthy S; Leoni L; Lukens J; Bhuiyan M; Freifelder R; Kucharski A; Giurcanu M; Roman BB; Karczmar G; Kao CM; Halpern H; Chen CT
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4014-4024. PubMed ID: 35792927
[TBL] [Abstract][Full Text] [Related]
10. pO(2) Polarography versus positron emission tomography ([(18)F] fluoromisonidazole, [(18)F]-2-fluoro-2'-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia.
Gagel B; Reinartz P; Dimartino E; Zimny M; Pinkawa M; Maneschi P; Stanzel S; Hamacher K; Coenen HH; Westhofen M; Büll U; Eble MJ
Strahlenther Onkol; 2004 Oct; 180(10):616-22. PubMed ID: 15480509
[TBL] [Abstract][Full Text] [Related]
11. Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia.
Cho H; Ackerstaff E; Carlin S; Lupu ME; Wang Y; Rizwan A; O'Donoghue J; Ling CC; Humm JL; Zanzonico PB; Koutcher JA
Neoplasia; 2009 Mar; 11(3):247-59, 2p following 259. PubMed ID: 19242606
[TBL] [Abstract][Full Text] [Related]
12. The utility of multiparametric MRI to characterize hypoxic tumor subvolumes in comparison to FMISO PET/CT. Consequences for diagnosis and chemoradiation treatment planning in head and neck cancer.
Wiedenmann N; Grosu AL; Büchert M; Rischke HC; Ruf J; Bielak L; Majerus L; Rühle A; Bamberg F; Baltas D; Hennig J; Mix M; Bock M; Nicolay NH
Radiother Oncol; 2020 Sep; 150():128-135. PubMed ID: 32544609
[TBL] [Abstract][Full Text] [Related]
13. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
[TBL] [Abstract][Full Text] [Related]
14. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer.
Rajendran JG; Schwartz DL; O'Sullivan J; Peterson LM; Ng P; Scharnhorst J; Grierson JR; Krohn KA
Clin Cancer Res; 2006 Sep; 12(18):5435-41. PubMed ID: 17000677
[TBL] [Abstract][Full Text] [Related]
15. Reduction of [(18)F]fluoromisonidazole uptake after neoadjuvant chemotherapy for head and neck squamous cell carcinoma.
Yamane T; Kikuchi M; Shinohara S; Senda M
Mol Imaging Biol; 2011 Apr; 13(2):227-31. PubMed ID: 20552284
[TBL] [Abstract][Full Text] [Related]
16. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
Okamoto S; Shiga T; Yasuda K; Ito YM; Magota K; Kasai K; Kuge Y; Shirato H; Tamaki N
J Nucl Med; 2013 Feb; 54(2):201-7. PubMed ID: 23321456
[TBL] [Abstract][Full Text] [Related]
17. PET measured hypoxia and MRI parameters in re-irradiated head and neck squamous cell carcinomas: findings of a prospective pilot study.
Rogasch J; Beck M; Stromberger C; Hofheinz F; Ghadjar P; Wust P; Budach V; Amthauer H; Tinhofer I; Furth C; Walter-Rittel TC; Zschaeck S
F1000Res; 2020; 9():1350. PubMed ID: 33796277
[No Abstract] [Full Text] [Related]
18. Correlation of (18)F-fluoromisonidazole PET findings with HIF-1α and p53 expressions in head and neck cancer: comparison with (18)F-FDG PET.
Norikane T; Yamamoto Y; Maeda Y; Kudomi N; Matsunaga T; Haba R; Iwasaki A; Hoshikawa H; Nishiyama Y
Nucl Med Commun; 2014 Jan; 35(1):30-5. PubMed ID: 24121312
[TBL] [Abstract][Full Text] [Related]
19. Multiparametric [18F]Fluorodeoxyglucose/ [18F]Fluoromisonidazole Positron Emission Tomography/ Magnetic Resonance Imaging of Locally Advanced Cervical Cancer for the Non-Invasive Detection of Tumor Heterogeneity: A Pilot Study.
Pinker K; Andrzejewski P; Baltzer P; Polanec SH; Sturdza A; Georg D; Helbich TH; Karanikas G; Grimm C; Polterauer S; Poetter R; Wadsak W; Mitterhauser M; Georg P
PLoS One; 2016; 11(5):e0155333. PubMed ID: 27167829
[TBL] [Abstract][Full Text] [Related]
20. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study.
Lee NY; Mechalakos JG; Nehmeh S; Lin Z; Squire OD; Cai S; Chan K; Zanzonico PB; Greco C; Ling CC; Humm JL; Schöder H
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):2-13. PubMed ID: 17869020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
